[go: up one dir, main page]

HUE060121T2 - Anti-KRAS-G12D T-sejt receptorok - Google Patents

Anti-KRAS-G12D T-sejt receptorok

Info

Publication number
HUE060121T2
HUE060121T2 HUE17749580A HUE17749580A HUE060121T2 HU E060121 T2 HUE060121 T2 HU E060121T2 HU E17749580 A HUE17749580 A HU E17749580A HU E17749580 A HUE17749580 A HU E17749580A HU E060121 T2 HUE060121 T2 HU E060121T2
Authority
HU
Hungary
Prior art keywords
kras
cell receptors
receptors
cell
Prior art date
Application number
HUE17749580A
Other languages
English (en)
Inventor
Eric Tran
Yong-Chen Lu
Paul F Robbins
Steven A Rosenberg
Zhili Zheng
Original Assignee
The U S A As Represented By The Secretary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The U S A As Represented By The Secretary filed Critical The U S A As Represented By The Secretary
Publication of HUE060121T2 publication Critical patent/HUE060121T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
HUE17749580A 2016-08-02 2017-07-31 Anti-KRAS-G12D T-sejt receptorok HUE060121T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662369883P 2016-08-02 2016-08-02

Publications (1)

Publication Number Publication Date
HUE060121T2 true HUE060121T2 (hu) 2023-01-28

Family

ID=59564253

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17749580A HUE060121T2 (hu) 2016-08-02 2017-07-31 Anti-KRAS-G12D T-sejt receptorok

Country Status (20)

Country Link
US (5) US10611816B2 (hu)
EP (2) EP3494133B1 (hu)
JP (3) JP6993402B2 (hu)
KR (1) KR102527052B1 (hu)
CN (2) CN109790211B (hu)
AU (2) AU2017306038B2 (hu)
CA (1) CA3032870A1 (hu)
DK (1) DK3494133T3 (hu)
ES (1) ES2928051T3 (hu)
HR (1) HRP20221183T1 (hu)
HU (1) HUE060121T2 (hu)
IL (2) IL301894B2 (hu)
LT (1) LT3494133T (hu)
PL (1) PL3494133T3 (hu)
PT (1) PT3494133T (hu)
RS (1) RS63615B1 (hu)
SG (2) SG10201913959WA (hu)
SI (1) SI3494133T1 (hu)
SM (1) SMT202200379T1 (hu)
WO (1) WO2018026691A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060121T2 (hu) * 2016-08-02 2023-01-28 The U S A As Represented By The Secretary Anti-KRAS-G12D T-sejt receptorok
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EA202090652A1 (ru) 2017-09-20 2020-08-21 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras
KR102757789B1 (ko) 2017-10-05 2025-01-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 쥐 불변 영역을 갖는 tcr을 발현하는 세포를 선택적으로 확대시키는 방법
WO2019246286A1 (en) 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
EP3914270A4 (en) * 2019-01-25 2023-01-11 The Trustees of the University of Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING MUTANT RAS
JP2022521513A (ja) 2019-02-20 2022-04-08 フレッド ハッチンソン キャンサー リサーチ センター Rasネオ抗原に特異的な結合タンパク質およびその使用
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术(广东)有限公司 一种识别Kras G12V的高亲和力TCR
JP2022554349A (ja) * 2019-11-05 2022-12-28 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Hla拘束性hormad1 t細胞受容体およびその使用
AU2020408017A1 (en) 2019-12-20 2022-07-14 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
CN116034113A (zh) * 2019-12-30 2023-04-28 华夏英泰(北京)生物技术有限公司 一种增强型t细胞受体star及其应用
AU2021310213A1 (en) * 2020-07-13 2023-03-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II–restricted DRB T cell receptors against ras with g12d mutation
IL303106A (en) * 2020-11-25 2023-07-01 Geneius Biotechnology Inc Antigen specific t cells and methods of making and using same
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114920823B (zh) * 2022-05-27 2023-10-17 重庆医科大学 Tcr或其抗原结合片段及其应用
WO2024020537A2 (en) * 2022-07-22 2024-01-25 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN115850444B (zh) * 2022-09-15 2025-01-28 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117777270A (zh) * 2022-09-29 2024-03-29 广州医科大学 一种t细胞受体(tcr)及其用途
WO2024129720A2 (en) * 2022-12-13 2024-06-20 Biontech Us Inc. T cell receptor constructs and uses thereof
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US20020150891A1 (en) * 1994-09-19 2002-10-17 Leroy E. Hood Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
EP2102236B1 (en) 2007-01-12 2014-08-06 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services GP100-specific T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
SMT201700393T1 (it) 2010-09-20 2017-09-07 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Recettori di cellule t antigene-specifici ed epitopi di cellule t
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
PT3392270T (pt) 2011-09-15 2020-11-24 Us Health Recetores de células t que reconhecem mage restrito a hlaa1 ou hla-cw7
CA2853645A1 (en) * 2011-11-30 2013-06-06 National Cancer Center Induced malignant stem cells
CN105658206A (zh) * 2013-06-03 2016-06-08 诺华股份有限公司 抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
GB201314404D0 (en) 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
HUE065689T2 (hu) 2014-11-26 2024-06-28 The United States Of America Anti-mutált KRAS T sejt receptorok
JP7185524B2 (ja) 2015-09-15 2022-12-07 アメリカ合衆国 Hla-cw8拘束性の変異krasを認識するt細胞受容体
HUE060121T2 (hu) * 2016-08-02 2023-01-28 The U S A As Represented By The Secretary Anti-KRAS-G12D T-sejt receptorok

Also Published As

Publication number Publication date
EP3494133B1 (en) 2022-07-06
US11897933B2 (en) 2024-02-13
JP7413338B2 (ja) 2024-01-15
EP4159751A1 (en) 2023-04-05
US10611816B2 (en) 2020-04-07
US20220089677A1 (en) 2022-03-24
US20190177395A1 (en) 2019-06-13
CN109790211B (zh) 2024-03-26
IL301894B2 (en) 2025-02-01
IL264425A (hu) 2019-03-31
DK3494133T3 (da) 2022-09-19
IL301894B1 (en) 2024-10-01
US11840561B2 (en) 2023-12-12
SMT202200379T1 (it) 2022-11-18
IL301894A (en) 2023-06-01
US20240209059A1 (en) 2024-06-27
SG10201913959WA (en) 2020-03-30
ES2928051T3 (es) 2022-11-15
LT3494133T (lt) 2022-12-12
AU2017306038B2 (en) 2023-06-22
CA3032870A1 (en) 2018-02-08
JP2019527555A (ja) 2019-10-03
RS63615B1 (sr) 2022-10-31
JP2024045139A (ja) 2024-04-02
KR102527052B1 (ko) 2023-04-27
PT3494133T (pt) 2022-09-28
WO2018026691A1 (en) 2018-02-08
JP6993402B2 (ja) 2022-02-03
EP3494133A1 (en) 2019-06-12
US20200247869A1 (en) 2020-08-06
CN118063591A (zh) 2024-05-24
SI3494133T1 (sl) 2022-11-30
US20210300988A1 (en) 2021-09-30
IL264425B2 (en) 2023-09-01
KR20190064566A (ko) 2019-06-10
PL3494133T3 (pl) 2022-11-21
CN109790211A (zh) 2019-05-21
AU2017306038A1 (en) 2019-02-14
IL264425B1 (en) 2023-05-01
JP7649370B2 (ja) 2025-03-19
AU2023233125A1 (en) 2023-10-12
JP2022050400A (ja) 2022-03-30
HRP20221183T1 (hr) 2022-12-09
SG11201900654QA (en) 2019-02-27
US11208456B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
ZA201806862B (en) T cell receptors
ZA201806866B (en) T cell receptors
IL262144A (en) t cell receptors
ZA201806865B (en) T cell receptors
IL264425B1 (en) t cell receptors against kras-g20
PT3642224T (pt) Recetores de células t
ZA201701823B (en) T cell receptors
GB201522592D0 (en) T cell receptors
PL3286210T3 (pl) Receptor komórek t
PT3433270T (pt) Receptores de células t
PL3529267T3 (pl) Receptor komórek t
GB201518991D0 (en) T cell receptors